[1] Bepler G, Begum M, Simon GR. Molecular analysis-based treatment strategies for non-small cell lung cancer[J]. Cancer Control,2008, 15(2):130-139. [2] 陆舜,虞永峰,纪文翔. 2015年肺癌诊疗指南:共识和争议[J]. 解放军医学杂志,2016,41(1):1-6. [3] Cadranel J, Zalcman G, Sequist L. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer[J]. Eur Respir J,2011, 37(1):183-193. [4] Tsujioka H, Yotsumoto F, Shirota K, et al. Emerging strategies for ErbB ligand-based targeted therapy for cancer[J]. Anticancer Res, 2010,30(8):3107-3112. [5] Greenhalgh J, Dwan K, Boland A, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2016(5):CD010383. [6] Zheng D, Ye X, Zhang MZ, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance[J]. Sci Rep, 2016, 12(6):20913. [7] Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer[J].Clin Cancer Res, 2010,16(22):5489-5498. [8] Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007,316(5827):1039-1043. [9] Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J]. Sci Transl Med, 2011, 3(75):75ra26. [10] Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1[J]. Proc Nat Acad Sci USA, 2012, 109(31):E2127-2133. [11] Yatabe Y. EGFR mutations and the terminal respiratory unit[J].Cancer Metastasis Rev, 2010,29(1):23-36. [12] Wang L, Wang R, Pan Y, et al. The pemetrexed-containing treatments in the non-small cell lung cancer is-/low thymidylate synthase expression better than +/high thymidylate synthase expression:a meta-analysis[J]. BMC Cancer, 2014,14:205. [13] Boulay BR, Parepally M. Managing malignant biliary obstruction in pancreas cancer:choosing the appropriate strategy[J]. World J Gastroenterol,2014,20(28):9345-9353. [14] Vogel A, Kullmann F, Kunzmann V, et al. Patients with advanced pancreatic cancer and hyperbilirubinaemia:review and german expert opinion on treatment with nab-paclitaxel plus gemcitabine[J]. Oncol Res Treat, 2015, 38(11):596-603. [15] Flaherty KT, Hamilton BK, Rosen MA, et al. Phase Ⅰ/Ⅱ trial of imatinib and bevacizumab in patients with advanced melanoma and other advanced cancers[J]. Oncologist, 2015, 20(8):952-959. [16] Terasawa T, Koja S, Yasuda K, et al. A case of metastatic colorectal cancer with icterus due to multiple liver metastases treated effectively by FOLFOX plus bevacizumab[J]. Gan To Kagaku Ryoho, 2013,40(8):1115-1118. [17] Camacho LH, Garcia S, Panchal AM, et al. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases[J]. Clin Colorectal Cancer, 2010, 9(5):311-314. [18] Bauerle KT, Schweppe RE, Lund G, et al. Nuclear factor kappaB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8[J]. J Clin Endocrinol Meta,2014,99(8):E1436-1444. [19] 程刚,艾斌. 表皮生长因子受体酪氨酸激酶抑制剂耐药后非小细胞肺癌治疗研究进展[J]. 中国肿瘤临床,2015,42(19):942-946. [20] 袁冬梅,宋勇.非小细胞肺癌治疗新时代:免疫治疗[J].解放军医学杂志,2017,42(6):483-487. |